drugset / Trial / NCT04653038
A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, multi-cohort, multi-center Phase I clinical trial to evaluate the efficacy and safety of MGD013 in ① Cohort 1: patients with unresectable, recurrent or metastatic melanoma who have failed prior immune checkpoint inhibitor therapy; ② Cohort 2: patients with untreated, unresectable recurrent or metastatic, mucosal or acral lentiginous melanoma.
Timeline
- Start
- 2020-10-29
- Primary completion
- 2022-03-02
- Completion
- 2022-03-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tebotelimab | Protein / enzyme biologic | 600 mg | Intravenous |